SPIKES

Last updated

The SPIKES protocol is a method used in clinical medicine to break bad news to patients and families. [1] [2] [3] [4] [5] [6] [7] As receiving bad news can cause distress and anxiety, [7] clinicians need to deliver the news carefully. [8] By using the SPIKES method for introducing and communicating information to patients and their families, it can aid in the presentation of the material. The SPIKES method is helpful in providing an organized manner of communication during situations that are typically complex and difficult to communicate. According to research related to the SPIKES method, important factors to consider when using this protocol involve empathy, acknowledgement and validation of feelings, providing information about intervention and treatment, and ensuring that the patient understands the news being delivered. [1]

The protocol was first proposed in 2000 by Baile et al, in the context of oncology. [9] [10]

The name SPIKES is an acronym, where the letters stand for: [9] [1] [8]

→ This entails never to give bad news by use of phone or in a hallway. One may consider to sit in a private space or room with no distractions so to be sure the message being delivered is the one focused on; no use of televisions or cellphones. Ensure that you face both the patient and the family and establish therapeutic alliance or connection by use of eye contact and physical touch, i.e. holding a hand or touching an arm.

→ Begin by asking the patient what they believe is going on. This not only allows you to find out what they know about the situation, but also engages the patient. It allows for them to realize what they think matters, and forms a starting point for how to proceed. It is important to listen to what the patient tells you as this is the first place to correct any misconceptions that are held right away. [11] [12]

→ Using phrases such as "Shall I share the results of the scan with you now?" or "Is this a good time to share with you what I believe is going on?" allow for the patient to decide if they are ready to hear more and also allows for open discussion to follow. Phrasing is important as you are essentially asking for permission to share unpleasant news with them. The way it is worded shows respect for the patient's feelings and reflects on their readiness to receive news. [11]

→ Speak slowly, maintain eye contact, and use terms both parties can understand. This is the time to explain what the bad news means for the patient. Beware of adding extra details right away as this is the place to be clear and concise of what is happening.

→ Often it is hard to fully understand what is going through the patient's or families' minds. Silence is often best instead of speaking out as everyone is processing emotions. When you feel it is the right time to speak, speak out of empathy and acknowledge that your patient is feeling something. Do not discourage tears or silence, this may be a processing strategy that is necessary to fully come to terms with the situation. Provide support. [11]

→ Summarize all thoughts and decide where to go from here. Options to discuss may be treatment, setting another meeting, discussing hospice care, or many others. Each situation is unique and it is best to do what is in the best interest of the patient's needs and wants. [13]

Related Research Articles

Experimental cancer treatments are mainstream medical therapies intended to treat cancer by improving on, supplementing or replacing conventional methods. However, researchers are still trying to determine whether these treatments are safe and effective treatments. Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions. Health insurance and publicly funded health care programs normally refuse to pay for experimental cancer treatments.

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

Palliative care is an interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex, and often terminal illnesses. Within the published literature, many definitions of palliative care exist. The World Health Organization (WHO) describes palliative care as "an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual". In the past, palliative care was a disease specific approach, but today the WHO takes a broader patient-centered approach that suggests that the principles of palliative care should be applied as early as possible to any chronic and ultimately fatal illness. This shift was important because if a disease-oriented approach is followed, the needs and preferences of the patient are not fully met and aspects of care, such as pain, quality of life, and social support, as well as spiritual and emotional needs, fail to be addressed. Rather, a patient-centered model prioritizes relief of suffering and tailors care to increase the quality of life for terminally ill patients.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, it is possible for an afflicted individual to experience difficulty in breathing.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept though some authors and organisations use these expressions separately to indicate particular nuances.

<span class="mw-page-title-main">Cancer survivor</span> Person with cancer who is still alive


A cancer survivor is a person with cancer of any type who is still living. Whether a person becomes a survivor at the time of diagnosis or after completing treatment, whether people who are actively dying are considered survivors, and whether healthy friends and family members of the cancer patient are also considered survivors, varies from group to group. Some people who have been diagnosed with cancer reject the term survivor or disagree with some definitions of it.

Robert Alexander Amiel Buckman was a British doctor of medicine, comedian and author, and president of the Humanist Association of Canada. He first appeared in a Cambridge University Footlights Revue in 1968, and subsequently presented several television and radio programmes about medicine, as well as appearing on comedy programmes such as Just a Minute. He was also the author of many popular books on medicine.

Psycho-oncology is an interdisciplinary field at the intersection of physical, psychological, social, and behavioral aspects of the cancer experience for both patients and caregivers. Also known as psychiatric oncology or psychosocial oncology, researchers and practitioners in the field are concerned with aspects of individuals' experience with cancer beyond medical treatment, and across the cancer trajectory, including at diagnosis, during treatment, transitioning to and throughout survivorship, and approaching the end-of-life. Founded by Jimmie Holland in 1977 via the incorporation of a psychiatric service within the Memorial Sloan Kettering Cancer Center in New York, the field has expanded drastically since and is now universally recognized as an integral component of quality cancer care. Cancer centers in major academic medical centers across the country now uniformly incorporate a psycho-oncology service into their clinical care, and provide infrastructure to support research efforts to advance knowledge in the field.

<span class="mw-page-title-main">Dihydropyrimidine dehydrogenase deficiency</span> Medical condition

Dihydropyrimidine dehydrogenase deficiency is an autosomal recessive metabolic disorder in which there is absent or significantly decreased activity of dihydropyrimidine dehydrogenase, an enzyme involved in the metabolism of uracil and thymine.

<span class="mw-page-title-main">Radiation treatment planning</span>

In radiotherapy, radiation treatment planning (RTP) is the process in which a team consisting of radiation oncologists, radiation therapist, medical physicists and medical dosimetrists plan the appropriate external beam radiotherapy or internal brachytherapy treatment technique for a patient with cancer.

<span class="mw-page-title-main">Tomotherapy</span> Type of radiation therapy

Tomotherapy is a type of radiation therapy treatment machine. In tomotherapy a thin radiation beam is modulated as it rotates around the patient, while they are moved through the bore of the machine. The name comes from the use of a strip-shaped beam, so that only one “slice” of the target is exposed at any one time by the radiation. The external appearance of the system and movement of the radiation source and patient can be considered analogous to a CT scanner, which uses lower doses of radiation for imaging. Like a conventional machine used for X-ray external beam radiotherapy, a linear accelerator generates the radiation beam, but the external appearance of the machine, the patient positioning, and treatment delivery is different. Conventional linacs do not work on a slice-by-slice basis but typically have a large area beam which can also be resized and modulated.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

Nicholas James Gonzalez was a New York–based physician known for developing the Gonzalez regimen, an alternative cancer treatment. Gonzalez's treatments are based on the belief that pancreatic enzymes are the body's main defense against cancer and can be used as a cancer treatment. His methods have been generally rejected by the medical community. and he has been characterized as a quack and fraud by other doctors and health fraud watchdog groups. In 1994 Gonzalez was reprimanded and placed on two years' probation by the New York state medical board for "departing from accepted practice".

<span class="mw-page-title-main">Medication-related osteonecrosis of the jaw</span> Medical condition

Medication-related osteonecrosis of the jaw is progressive death of the jawbone in a person exposed to a medication known to increase the risk of disease, in the absence of a previous radiation treatment. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

<span class="mw-page-title-main">Osteoradionecrosis</span> Osteoradionecrosis is an Acute form of Osteomyelitis

Osteoradionecrosis (ORN) is a serious complication of radiation therapy in cancer treatment where radiated bone becomes necrotic and exposed. ORN occurs most commonly in the mouth during the treatment of head and neck cancer, and can arise over 5 years after radiation. Common signs and symptoms include pain, difficulty chewing, trismus, mouth-to-skin fistulas and non-healing ulcers.

<span class="mw-page-title-main">Intravenous ascorbic acid</span> Nonmedical procedure

Intravenous Ascorbic Acid, is a process that delivers soluble ascorbic acid directly into the bloodstream. It is not approved for use to treat any medical condition.

Mhoira E.H. LengFRSE MBChB MRCP(UK) FRCP(Ed and Glas) is one of the first Scottish specialists in palliative care, who has developed the palliative care services internationally, working in Eastern Europe, India and Africa and advises international institutions and agencies on palliative care in the developing world. In 2021, Leng was admitted as one of the new female Fellows of the Royal Society of Edinburgh.

Theranostics, also known as theragnostics, is an emerging field in precision medicine that combines diagnostic and therapeutic approaches to provide the potential for personalized treatment and real-time monitoring of the effectiveness of treatments. Improvements in imaging techniques and targeted therapies are the basis of the field of theranostics. When medical imaging is coupled with the development of novel radiotracers and contrast agents, theranostics may provide opportunities for precise diagnosis and targeted therapy.

References

  1. 1 2 3 Kaplan, Marcelle (1 August 2010). "SPIKES: A Framework for Breaking Bad News to Patients With Cancer". Clinical Journal of Oncology Nursing. 14 (4): 514–516. doi:10.1188/10.CJON.514-516. PMID   20682509.
  2. ↑ Dean, Antonia; Willis, Susan (2 June 2016). "The use of protocol in breaking bad news: evidence and ethos" (PDF). International Journal of Palliative Nursing. 22 (6): 265–271. doi:10.12968/ijpn.2016.22.6.265. PMID   27349844.
  3. ↑ Seifart, C.; Hofmann, M.; Bär, T.; Riera Knorrenschild, J.; Seifart, U.; Rief, W. (2014). "Breaking bad news–what patients want and what they get: evaluating the SPIKES protocol in Germany". Annals of Oncology. 25 (3): 707–711. doi:10.1093/annonc/mdt582. PMC   4433514 . PMID   24504443.
  4. ↑ de Moura Villela, Edlaine Faria; Bastos, Luana Kronit; de Almeida, Wanderson Sant’ana; Pereira, Andressa Oliveira; de Paula Rocha, Matheus Silva; de Oliveira, Fábio Morato; Bollela, Valdes Roberto (14 February 2020). "Effects on Medical Students of Longitudinal Small-Group Learning about Breaking Bad News". The Permanente Journal. 24 (2). doi:10.7812/TPP/19.157. PMC   7039420 . PMID   32097117.
  5. ↑ Servotte, Jean-Christophe; Bragard, Isabelle; Szyld, Demian; Van Ngoc, Pauline; Scholtes, Béatrice; Van Cauwenberge, Isabelle; Donneau, Anne-Françoise; Dardenne, Nadia; Goosse, Manon; Pilote, Bruno; Guillaume, Michèle; Ghuysen, Alexandre (November 2019). "Efficacy of a Short Role-Play Training on Breaking Bad News in the Emergency Department". Western Journal of Emergency Medicine. 20 (6): 893–902. doi:10.5811//westjem.2019.8.43441. PMC   6860397 . PMID   31738716.
  6. ↑ Alves, Carolina Guimarães Bonfim; Treister, Nathaniel Simon; Ribeiro, Ana Carolina Prado; Brandão, Thaís Bianca; Tonaki, Juliana Ono; Lopes, Marcio Ajudarte; Rivera, César; Santos-Silva, Alan Roger (November 28, 2019). "Strategies for communicating oral and oropharyngeal cancer diagnosis: why talk about it?". Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 129 (4): 347–356. doi:10.1016/j.oooo.2019.11.014. PMID   31928903. S2CID   210191704.
  7. 1 2 Zheng, Ying; Lei, Fang; Liu, Bao (14 December 2019). "Cancer Diagnosis Disclosure and Quality of Life in Elderly Cancer Patients". Healthcare. 7 (4): 163. doi: 10.3390/healthcare7040163 . PMC   6956195 . PMID   31847309.
  8. 1 2 "Ask the Hematologist: SPIKES Protocol For Delivering Bad News to Patients". Hematology.org. July 1, 2017.
  9. 1 2 Baile, Walter F.; Buckman, Robert; Lenzi, Renato; Glober, Gary; Beale, Estela A.; Kudelka, Andrzej P. (August 2000). "SPIKES—A Six‐Step Protocol for Delivering Bad News: Application to the Patient with Cancer". The Oncologist. 5 (4): 302–311. doi: 10.1634/theoncologist.5-4-302 . PMID   10964998.
  10. ↑ "Breaking bad news - The MDU". Themdu.com.
  11. 1 2 3 "Course : Course: To Err is Human" (PDF). Who.int. Retrieved 27 November 2021.
  12. ↑ Monden, Kimberley R.; Gentry, Lonnie; Cox, Thomas R. (11 December 2017). "Delivering Bad News to Patients". Baylor University Medical Center Proceedings. 29 (1): 101–102. doi:10.1080/08998280.2016.11929380. PMC   4677873 . PMID   26722188.
  13. ↑ Mostafavian, Zahra; Shaye, ZahraAbbasi (2018). "Evaluation of physicians' skills in breaking bad news to cancer patients". Journal of Family Medicine and Primary Care. 7 (3): 601–605. doi: 10.4103/jfmpc.jfmpc_25_18 . PMC   6069664 . PMID   30112317.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.